Download Free Medical United Nations Office on Drugs and Crime (UNODC) World Drug Report 2020

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2020 - Booklet 4.5 PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : United Nations Office on Drugs and Crime (UNODC) World Drug Report 2020 is presented in six separate booklets. The report gives detailed information and analysis to support the international community in implementing operational recommendations present in the outcome document of the special session of the General Assembly on the world drug problem, held in 2016 Booklet 4 of the United Nations Office on Drugs and Crime (UNODC) World Drug Report 2020 has five sub-booklets and addresses a number of crosscutting issues, including the macrodynamics that are driving the expansion and increasing complexity of the drug markets. These booklets also describe some of the rapidly evolving drug-related concerns including, multifaceted global opioid crisis, rapid market changes, the market for new psychoactive substances, the use of the darknet for supplying drugs, and developments in jurisdictions t

Tags : United Nations Office on Drugs and Crime, UNODC, summary, World Drug Report 2020, General Assembly, world drug problem, New Psychoactive Substances, NPS

Published on : Jun 30, 2020 | Views : 1562 | Downloads : 4

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Seizures of both plant NPS based and synthetic NPS declined in 2018
Slide 2-

New Psychoactive Substances Global seizures of khat, fluctuating strongly year on year, declined over the period 2013-2018 as compared to the period 2008-2012, notably reflecting less quantities reported seized in Asia.
Slide 3-

New Psychoactive Substances Following the introduction of legislation on mephedrone in 2010, mephedrone use declined and following NPS legislation in 2016, use of NPS declined. Ketamine use, however, increased in recent years.
Slide 4-

New Psychoactive Substances Following the introduction of several waves of controls of NPS over the 2010-2012 period, use of NPS declined.
Slide 5-

New Psychoactive Substances Following the introduction on NPS legislation, in Austria (2008 and 2012) use of NPS remained low in Austria. NPS use appears to have increased in Germany for several years; once NPS legislation was introduced in 2016, NPS use stopped growing.
Slide 6-

New Psychoactive Substances Despite of ongoing scheduling, there are three times as many identified NPS than there are psychoactive substances under international control.
Slide 7-

New Psychoactive Substances Most identified NPS are stimulants (synthetic cathinones and phenetylamines), followed by synthetic cannabinoids (“spice” products). Most of the identified opioids have been fentanyl analogues.
Slide 8-

New Psychoactive Substances Overall number of identified NPS by Member States has begun to stabilize after 2015 while NPS with opioid effects have been still growing strongly until 2017 before showing first signs of stabilisation.

User Presentation
Related Presentations

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2020 - Booklet 1

About : An experienced pharma professional managing sales, marketing and brand management of top global pharma products Presently leading a team of experts in the development and execution of pharma eCommerce strategies that support GSK products to HCP customers.
Occupation : Medical Professional
Specialty : Other Health Professionals
Country : United States of America
Website :

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2020 - Booklet 1

Consumer-Directed Healthcare

DOI System (Digital Object Identifier System): overview

Evaluate Vantage Pharma, Biotech & Medtech 2019 in Review

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2019 - Booklet 1

Self-Nano Emulsifying Drug-Delivery Systems

Drug Development-Basic Overview of Clinical Trials

Drug Formulary Development and Management

Drug development planning through to late stage challenges

Molecular Targets in Cancer Drug Development

HEALTH A TO Z